Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 2229

1.

Antifibrinolytics for heavy menstrual bleeding.

Bryant-Smith AC, Lethaby A, Farquhar C, Hickey M.

Cochrane Database Syst Rev. 2018 Apr 15;4:CD000249. doi: 10.1002/14651858.CD000249.pub2. Review.

PMID:
29656433
2.

Current understanding on pharmacokinetics, clinical efficacy and safety of progestins for treating pain associated to endometriosis.

Barra F, Scala C, Ferrero S.

Expert Opin Drug Metab Toxicol. 2018 Apr;14(4):399-415. doi: 10.1080/17425255.2018.1461840. Epub 2018 Apr 10. Review.

PMID:
29617576
3.

Long-Term Effects of Gonadotropin-Releasing Hormone Agonists and Add-Back in Adolescent Endometriosis.

Gallagher JS, Missmer SA, Hornstein MD, Laufer MR, Gordon CM, DiVasta AD.

J Pediatr Adolesc Gynecol. 2018 Aug;31(4):376-381. doi: 10.1016/j.jpag.2018.03.004. Epub 2018 Mar 15.

PMID:
29551430
4.

Shifting from Oral Contraceptives to Norethisterone Acetate, or Vice Versa, because of Drug Intolerance: Does the Change Benefit Women with Endometriosis?

Vercellini P, Ottolini F, Frattaruolo MP, Buggio L, Roberto A, Somigliana E.

Gynecol Obstet Invest. 2018;83(3):275-284. doi: 10.1159/000486335. Epub 2018 Feb 27.

5.

Norethindrone acetate versus extended-cycle oral contraceptive (Seasonique®) in the treatment of endometriosis symptoms: A prospective open-label comparative study.

Scala C, Leone Roberti Maggiore U, Barra F, Venturini PL, Ferrero S.

Eur J Obstet Gynecol Reprod Biol. 2018 Mar;222:89-94. doi: 10.1016/j.ejogrb.2018.01.022. Epub 2018 Feb 3.

PMID:
29408753
6.

Gonadotropin-Releasing Hormone Receptor Antagonist Mono- and Combination Therapy With Estradiol/Norethindrone Acetate Add-Back: Pharmacodynamics and Safety of OBE2109.

Pohl O, Marchand L, Fawkes N, Gotteland JP, Loumaye E.

J Clin Endocrinol Metab. 2018 Feb 1;103(2):497-504. doi: 10.1210/jc.2017-01875.

PMID:
29216361
7.

Norethisterone enanthate-induced cerebral venous sinus thrombosis (CVST).

Bahall M, Santlal M.

BMJ Case Rep. 2017 Nov 14;2017. pii: bcr-2017-222418. doi: 10.1136/bcr-2017-222418.

8.

Thromboembolic adverse event study of combined estrogen-progestin preparations using Japanese Adverse Drug Event Report database.

Hasegawa S, Matsui T, Hane Y, Abe J, Hatahira H, Motooka Y, Sasaoka S, Fukuda A, Naganuma M, Hirade K, Takahashi Y, Kinosada Y, Nakamura M.

PLoS One. 2017 Jul 21;12(7):e0182045. doi: 10.1371/journal.pone.0182045. eCollection 2017.

9.

Brief Report: Dapivirine Vaginal Ring Use Does Not Diminish the Effectiveness of Hormonal Contraception.

Balkus JE, Palanee-Phillips T, Reddy K, Siva S, Harkoo I, Nakabiito C, Kintu K, Nair G, Chappell C, Kiweewa FM, Kabwigu S, Naidoo L, Jeenarain N, Marzinke M, Soto-Torres L, Brown ER, Baeten JM.

J Acquir Immune Defic Syndr. 2017 Oct 1;76(2):e47-e51. doi: 10.1097/QAI.0000000000001455.

10.

Efficacy and acceptability of long-term norethindrone acetate for the treatment of rectovaginal endometriosis.

Morotti M, Venturini PL, Biscaldi E, Racca A, Calanni L, Vellone VG, Stabilini C, Ferrero S.

Eur J Obstet Gynecol Reprod Biol. 2017 Jun;213:4-10. doi: 10.1016/j.ejogrb.2017.03.033. Epub 2017 Mar 27.

PMID:
28384540
11.

Impact of various progestins with or without transdermal testosterone on gonadotropin levels for non-invasive hormonal male contraception: a randomized clinical trial.

Zitzmann M, Rohayem J, Raidt J, Kliesch S, Kumar N, Sitruk-Ware R, Nieschlag E.

Andrology. 2017 May;5(3):516-526. doi: 10.1111/andr.12328. Epub 2017 Feb 11.

12.

Progestin-only pills may be a better first-line treatment for endometriosis than combined estrogen-progestin contraceptive pills.

Casper RF.

Fertil Steril. 2017 Mar;107(3):533-536. doi: 10.1016/j.fertnstert.2017.01.003. Epub 2017 Feb 2. Review.

PMID:
28162779
13.

Hepatic Adenomas in Adolescents and Young Women with Endometriosis Treated with Norethindrone Acetate.

Brady PC, Missmer SA, Laufer MR.

J Pediatr Adolesc Gynecol. 2017 Jun;30(3):422-424. doi: 10.1016/j.jpag.2016.12.002. Epub 2016 Dec 23.

PMID:
28024920
14.

Injectable contraception: updates and innovation.

Schivone G, Dorflinger L, Halpern V.

Curr Opin Obstet Gynecol. 2016 Dec;28(6):504-509. Review.

PMID:
27787287
15.

Postmenopausal Hormone Therapy and Breast Cancer Prognostic Characteristics: A Linkage between Nationwide Registries.

Román M, Graff-Iversen S, Weiderpass E, Vangen S, Sakshaug S, Hofvind S, Ursin G.

Cancer Epidemiol Biomarkers Prev. 2016 Nov;25(11):1464-1473. Epub 2016 Jul 26.

16.

Efficacy and Safety of an Injectable Combination Hormonal Contraceptive for Men.

Behre HM, Zitzmann M, Anderson RA, Handelsman DJ, Lestari SW, McLachlan RI, Meriggiola MC, Misro MM, Noe G, Wu FC, Festin MP, Habib NA, Vogelsong KM, Callahan MM, Linton KA, Colvard DS.

J Clin Endocrinol Metab. 2016 Dec;101(12):4779-4788. Epub 2016 Oct 27.

PMID:
27788052
17.

Evaluation of an ultra-low-dose oral contraceptive for dysmenorrhea: a placebo-controlled, double-blind, randomized trial.

Harada T, Momoeda M.

Fertil Steril. 2016 Dec;106(7):1807-1814. doi: 10.1016/j.fertnstert.2016.08.051. Epub 2016 Oct 4.

PMID:
27717552
18.

A comparison of progestins within three classes: Differential effects on learning and memory in the aging surgically menopausal rat.

Braden BB, Andrews MG, Acosta JI, Mennenga SE, Lavery C, Bimonte-Nelson HA.

Behav Brain Res. 2017 Mar 30;322(Pt B):258-268. doi: 10.1016/j.bbr.2016.06.053. Epub 2016 Jun 28.

20.

Dra tillbaka varningen för Primolut-Nor (noretisteronacetat) - Skrämsel utan evidens främjar inte den reproduktiva hälsan.

Brynhildsen J.

Lakartidningen. 2016 Jun 10;113. pii: D4TH. Swedish. No abstract available.

Supplemental Content

Loading ...
Support Center